We are Sorry, This Page doesn't Exist

HIGHLIGHTS Revenues of $179.7 million, up 33% from the previous year. The outcome of an out of c.....»»

50% of Enrollment Complete for Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020 Topline Data Expected Second Quarter 2020 Based on Cu.....»»

Shares of Align Technology, Inc. (NASDAQ: ALGN) — maker of Invisalign — plummeted Thursday in reaction to the company's second-quarter earnings report and guidance but CEO Joe Hogan.....»»

Shares of Align Technology, Inc. (NASDAQ: ALGN) — maker of Invisalign — plummeted Thursday in reaction to the company's second-quarter earnings report and gui read more.....»»

HIGHLIGHTS Revenues of $135.1 million, down compared with the previous year as a results o.....»»

TORONTO, March 12, 2019 (GLOBE NEWSWIRE) -- The Becker Milk Company Limited (the "Company") (TSX-BEK.B) is pleased to report the results for the nine months ended January 31, 2019. HIGHLIGHTS Total revenues for the nine months ended January 31, 2019 w.....»»

ADF Group Inc. annonces the results for the fiscal year ended January 31, 2018 Canada NewsWire TERREBONNE, QC, April 12, 2018 HIGHLIGHTS Revenues up by 75% compared with the previous year, reaching $180.5 million. Revenues before income tax expens.....»»

Jim Cramer highlights the companies that wowed analysts and investors with their mid-2018 earnings results......»»

1st Quarter 2024 Highlights: Net income was.....»»

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (NASDAQ:XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the year ended December 31, 2023. Recent Highlights: The Company.....»»

– REC.....»»

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. Latest Ratings for A.....»»

BOCA RATON, Fla., May 17, 2021 (GLOBE NEWSWIRE) -- Spectrum Global Solutions, Inc. (the "Company") (OTCQB:SGSI) reported financial results for the three months ended March 31, and provides a Management Discussion and Analysis. Th.....»»

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squ.....»»

Revenues Improve 65.9%; Diluted EPS of $0.02 Key Acquisition of Tellenger, Inc. Completed Subsequent to Quarter End FAIRFAX, Va., May 14, 2021 (GL.....»»

- Anticipate Emergency Use Submission for SARS-CoV-2Antibody Biosensor.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong fi.....»»

FIRST QUARTER HIGHLIGHTS Q1 top line grew 2% vs 2019 pre-COVID-19 baseline and -3.6% vs 2020 despite m.....»»

SÃO PAULO, May 13, 2021 /PRNewswire/ -- CCR S.A. (CCR), one of Latin America's largest infrastructure concession groups, discloses its results for the 1st quarter of 2021. Highlights 1Q21 vs. 1Q20 Consolidated traffic increased by 1.7%.....»»